Over time, fewer people taking GLP-1 receptor agonists developed epilepsy compared with those taking DPP-4 inhibitors (2.35% versus 2.41%, respectively)
Novo has developed a strong lead with UBSs forecasts projecting 400k total prescriptions at the end of Q1, with the majority of sales coming through cash-pay channels capturing net-new GLP-1 users
The Rise of Peptide Therapy in Modern Wellness Peptides Are the Next Frontier in Wellness and Performance In recent years, peptide therapy has transitioned from being an obscure topic in scientific journals to a mainstream biohacking trend embraced by athletes, longevity seekers, and wellness enthusiasts alike
Cleveland Clinic October 19, 2021
Retrieved from DOI: 10.1097/01.NURSE.0000441246.36711.66 Wittmer Rejuvenation Clinic
Circulation 80 , 14491457 (1989)